Prophylaxis
33
4
4
17
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.1%
2 terminated out of 33 trials
89.5%
+3.0% vs benchmark
42%
14 trials in Phase 3/4
24%
4 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (33)
Monitoring of Anti-TFPI in Hemophilia
Vitamin c Supplementation in the Prevention of CRPS Following Distal Radius Fractures
Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS)
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes
Regional and Intravenous Dexamethasone in The Prophylaxis of Rebound Pain After Supraclavicular Block in Upper Limb Surgeries
Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW
L-AmB_ Retrospective mUlticenter Study on Mycosis prOphylaxis
Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty
Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
Efficacy of Flunarizine Vs Amitriptyline in Prophylaxis of Migraine Prophylaxis
Study of Low Molecular Weight Heparins
A Long Term Safety Study of BCX7353 in Hereditary Angioedema
Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers
Escalating Monthly Doses of Tafenoquine in Healthy Volunteers
Lactobacillus Reuteri DSM 17938 in Gut Microbiota Development in Infant Born by Caesarean Section